THROMBOMODULIN

Description

Recombinant thrombomodulin, an anticoagulant, was approved and launched in Japan for the intravenous treatment of DIC. DIC is a blood clotting disorder in which the blood coagulation system becomes overactive, leading to blockage of capillaries, ischemia and other damage to vascular endothelial cells, and organ damage. Concurrently, the use and subsequent depletion of platelets and coagulation proteins resulting from the ongoing coagulation may induce severe bleeding. DIC frequently occurs as a complication of malignant tumors and infections. Bleeding is typically the presenting symptom in patients with DIC, a factor that can complicate decisions about treatment. Thrombomodulin is an endothelial cell membrane glycoprotein that neutralizes thrombin pro-coagulant activity and accelerates the thrombin-catalyzed activation of anticoagulant protein C, thus allowing potential use in the treatment of thrombotic disorders such as DIC.

Originator

Asahi Kasei Pharma (Japan)

brand name

Recomodulin

Raw materials

Preparation Products